[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586305":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":32,"centralContacts":37,"locations":48,"responsibleParty":66,"collaborators":69,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":23,"enrollmentInfo":83,"targetDuration":23,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":51,"whyStopped":23,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Active treatment followed by placebo","ACTIVE_COMPARATOR","Canagliflozin 300 mg once daily for 5 weeks (double-blind), followed by matching placebo once daily for 5 weeks (double-blind), followed by canagliflozin 300 mg once daily for 16 weeks (open label)",[13],"Drug: Canagliflozin 300 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo followed by active treatment","PLACEBO_COMPARATOR","Placebo once daily for 5 weeks (double-blind), followed by canagliflozin 300 mg once daily for 5 weeks (double-blind), followed by canagliflozin 300 mg once daily for 16 weeks (open label)",[13],{"label":20,"type":21,"description":22,"interventionNames":23},"Standard of care","NO_INTERVENTION","Standard of care, with no active treatment, for 26 weeks (open label)",null,[25],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Canagliflozin 300 MG","Canagliflozin 300 mg once daily",[9,15],[31],"Invokana 300 mg",[33],{"name":34,"affiliation":35,"role":36},"Thomas A. Mavrakanas, MD, MSc.","Research Institute-McGill University of Health Centre","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Efrosyne Tsirella","CONTACT","514-934-1934","37836","efrosyne.tsirella@muhc.mcgill.ca",{"name":45,"role":40,"phone":41,"phoneExt":46,"email":47},"Norka Rios","35207","norka.rios@muhc.mcgill.ca",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":23,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Research Institute-McGill University Health Center","RECRUITING","Montreal","Quebec","Canada","CA",{"type":57,"coordinates":58},"Point",[59,60],-73.58781,45.50884,{"lat":60,"lon":59},[63,65],{"name":39,"role":40,"phone":64,"phoneExt":42,"email":43},"5149341934",{"name":45,"role":40,"phone":41,"phoneExt":46,"email":47},{"type":36,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Thomas Mavrakanas","Associate Professor",[70],{"name":71,"class":72},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100586305","phase-2-effect-of-canagliflozin-on-ultrafiltration--fibrosis-in-patients-on-peritoneal-dialysis-100586305",false,"NCT06913647","Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis","Effect of Canagliflozin on Ultrafiltration and Fibrosis in Peritoneal Dialysis: a a Proof-of-concept Randomized Phase II Crossover Clinical Trial","CAN-PD","Inclusion Criteria:\n\n* Adult patients with kidney failure on PD (both incident and prevalent) who are on a stable prescription of dextrose-based solutions for at least 3 months.\n* Only high or high-average transporters, as classified by PET, will be included.\n\nExclusion Criteria:\n\n* History of euglycemic ketoacidosis\n* Known hypersensitivity to canagliflozin\n* Active peritonitis or tunnel infection\n* Kidney transplant scheduled in the next 6 months\n* Severe liver cirrhosis (Child-Pugh class C stage)\n* Recurrent severe genital or urine infections\n* Patients receiving digoxin, phenobarbital, phenytoin, rifampin, or ritonavir if these agents cannot be safely discontinued\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":84,"type":85},30,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD.\n\nThe primary aim of this trial is to determine the short-term effects of canagliflozin, an SGLT-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test. The secondary aims are to determine the effect of canagliflozin on solute clearance and on effluent biomarkers of inflammation, angiogenesis, and fibrosis at 26 weeks. We hypothesize that canagliflozin will prevent glucose absorption by the peritoneal membrane, as compared with placebo, and will attenuate the development of inflammation, angiogenesis, and fibrosis of the peritoneal membrane, as assessed by relevant biomarkers in the dialysate.",[91,92],"ESRD","CKD (Chronic Kidney Disease) Stage 5D",[94,95,96,97,98],"SGLT-2 inhibitors","Canagliflozin","Ultrafiltration failure","Peritoneal fibrosis","Peritoneal dialysis","2026-03-12",{"date":101,"type":102},"2026-03-16","ACTUAL",{"date":104,"type":102},"2026-02-01",{"date":106,"type":85},"2028-12-31",{"name":5,"class":6},1]